Email updates

Keep up to date with the latest news and content from Critical Care and BioMed Central.

This article is part of the supplement: 33rd International Symposium on Intensive Care and Emergency Medicine

Open Badges Poster presentation

Dose-response of fibrinogen and factor XIII concentrate for correcting albumin-induced coagulopathy

US Schött*, DW Winstedt and JH Hanna

  • * Corresponding author: US Schött

Author Affiliations

Lund University, Lund, Sweden

For all author emails, please log on.

Critical Care 2013, 17(Suppl 2):P361  doi:10.1186/cc12299

The electronic version of this article is the complete one and can be found online at:

Published:19 March 2013

© 2013 Sch et al.; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Natural colloid albumin induces a lesser degree of dilutional coagulopathy than synthetic colloids. Fibrinogen concentrate has emerged as a promising strategy to treat coagulopathy, and factor XIII (FXIII) works synergistically with fibrinogen to correct coagulopathy following haemodilution with crystalloids. Objectives were to examine the ability of fibrinogen and FXIII concentrates to reverse albumin-induced dilutional coagulopathy.


High and low concentrations of both fibrinogen and FXIII were used to reverse coagulopathy induced by 1:1 dilution in vitro with 5% albumin of blood samples from healthy volunteers, monitored by rotational thromboelastometry (ROTEM).


Haemodilution with albumin significantly attenuated EXTEM maximum clot firmness (MCF), α angle (AA), clotting time (CT) and clot formation time (CFT), and FIBTEM MCF (P <0.001). Following haemodilution, both doses of fibrinogen significantly corrected all ROTEM parameters (P ≤0.02), except the lower dose did not correct AA. Compared with the lower dose, the higher dose of fibrinogen significantly improved FIBTEM MCF and EXTEM MCF, AA and CFT (P <0.001). The lower dose of FXIII did not significantly correct any of the ROTEM parameters, and the high dose only improved EXTEM CT (P = 0.004). All combinations of high/low concentrations of fibrinogen/ FXIII significantly improved all ROTEM parameters examined (P ≤0.001). Fibrinogen concentration generally had a greater effect on each parameter than did FXIII concentration; the best correction of ROTEM parameters was achieved with high-dose fibrinogen concentrate and either low-dose or high-dose FXIII.


Fibrinogen concentrate successfully corrected initiation, propagation and clot firmness deficits induced by haemodilution with albumin, and FXIII synergistically improved fibrin-based clot strength.


  1. Anesth Analg. 2008, 106:1360-1365. PubMed Abstract | Publisher Full Text OpenURL